The effects of sirolimus on wound healing in dermatologic surgery

Jerry D. Brewer, Clark C. Otley, Leslie J. Christenson, P. Kim Phillips, Randall K. Roenigk, Amy L. Weaver

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

BACKGROUND: Sirolimus, a TOR (target of rapamycin)-binding immunosuppressant, has been associated with wound healing complications; however, its effects have not been documented in dermatologic surgery. OBJECTIVE: The objective was to determine the effect of sirolimus on wound healing in dermatologic surgery. METHODS AND MATERIALS: Databases at Mayo Clinic were queried for organ transplant recipients undergoing dermatologic surgery. Medical records were reviewed retrospectively, and telephone interviews were conducted. Patients receiving sirolimus were compared with patients not receiving sirolimus. RESULTS: Postoperative infections occurred in 19.2% of the sirolimus group (n=26) and 5.4% of the controls (n=37; p=.11; odds ratio [OR], 4.2; 95% confidence interval [CI], 0.7-23.4). The incidence of wound dehiscence was greater in the sirolimus group (7.7% vs. 0%; p=.17; OR, 7.7; 95% CI, 0.4-166.3). CONCLUSION: No significantly increased risk of wound complications was found in organ transplant recipients receiving sirolimus while undergoing dermatologic surgery. However, this study was retrospective and had a small sample size. A larger study is necessary for corroboration.

Original languageEnglish (US)
Pages (from-to)216-223
Number of pages8
JournalDermatologic Surgery
Volume34
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Dermatologic Surgical Procedures
Sirolimus
Wound Healing
Odds Ratio
Confidence Intervals
Transplants
Wounds and Injuries
Immunosuppressive Agents
Sample Size
Medical Records
Retrospective Studies
Databases
Interviews

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Brewer, J. D., Otley, C. C., Christenson, L. J., Phillips, P. K., Roenigk, R. K., & Weaver, A. L. (2008). The effects of sirolimus on wound healing in dermatologic surgery. Dermatologic Surgery, 34(2), 216-223. https://doi.org/10.1111/j.1524-4725.2007.34040.x

The effects of sirolimus on wound healing in dermatologic surgery. / Brewer, Jerry D.; Otley, Clark C.; Christenson, Leslie J.; Phillips, P. Kim; Roenigk, Randall K.; Weaver, Amy L.

In: Dermatologic Surgery, Vol. 34, No. 2, 02.2008, p. 216-223.

Research output: Contribution to journalArticle

Brewer, JD, Otley, CC, Christenson, LJ, Phillips, PK, Roenigk, RK & Weaver, AL 2008, 'The effects of sirolimus on wound healing in dermatologic surgery', Dermatologic Surgery, vol. 34, no. 2, pp. 216-223. https://doi.org/10.1111/j.1524-4725.2007.34040.x
Brewer JD, Otley CC, Christenson LJ, Phillips PK, Roenigk RK, Weaver AL. The effects of sirolimus on wound healing in dermatologic surgery. Dermatologic Surgery. 2008 Feb;34(2):216-223. https://doi.org/10.1111/j.1524-4725.2007.34040.x
Brewer, Jerry D. ; Otley, Clark C. ; Christenson, Leslie J. ; Phillips, P. Kim ; Roenigk, Randall K. ; Weaver, Amy L. / The effects of sirolimus on wound healing in dermatologic surgery. In: Dermatologic Surgery. 2008 ; Vol. 34, No. 2. pp. 216-223.
@article{3970b265b023452c992fdb870839d0f3,
title = "The effects of sirolimus on wound healing in dermatologic surgery",
abstract = "BACKGROUND: Sirolimus, a TOR (target of rapamycin)-binding immunosuppressant, has been associated with wound healing complications; however, its effects have not been documented in dermatologic surgery. OBJECTIVE: The objective was to determine the effect of sirolimus on wound healing in dermatologic surgery. METHODS AND MATERIALS: Databases at Mayo Clinic were queried for organ transplant recipients undergoing dermatologic surgery. Medical records were reviewed retrospectively, and telephone interviews were conducted. Patients receiving sirolimus were compared with patients not receiving sirolimus. RESULTS: Postoperative infections occurred in 19.2{\%} of the sirolimus group (n=26) and 5.4{\%} of the controls (n=37; p=.11; odds ratio [OR], 4.2; 95{\%} confidence interval [CI], 0.7-23.4). The incidence of wound dehiscence was greater in the sirolimus group (7.7{\%} vs. 0{\%}; p=.17; OR, 7.7; 95{\%} CI, 0.4-166.3). CONCLUSION: No significantly increased risk of wound complications was found in organ transplant recipients receiving sirolimus while undergoing dermatologic surgery. However, this study was retrospective and had a small sample size. A larger study is necessary for corroboration.",
author = "Brewer, {Jerry D.} and Otley, {Clark C.} and Christenson, {Leslie J.} and Phillips, {P. Kim} and Roenigk, {Randall K.} and Weaver, {Amy L.}",
year = "2008",
month = "2",
doi = "10.1111/j.1524-4725.2007.34040.x",
language = "English (US)",
volume = "34",
pages = "216--223",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The effects of sirolimus on wound healing in dermatologic surgery

AU - Brewer, Jerry D.

AU - Otley, Clark C.

AU - Christenson, Leslie J.

AU - Phillips, P. Kim

AU - Roenigk, Randall K.

AU - Weaver, Amy L.

PY - 2008/2

Y1 - 2008/2

N2 - BACKGROUND: Sirolimus, a TOR (target of rapamycin)-binding immunosuppressant, has been associated with wound healing complications; however, its effects have not been documented in dermatologic surgery. OBJECTIVE: The objective was to determine the effect of sirolimus on wound healing in dermatologic surgery. METHODS AND MATERIALS: Databases at Mayo Clinic were queried for organ transplant recipients undergoing dermatologic surgery. Medical records were reviewed retrospectively, and telephone interviews were conducted. Patients receiving sirolimus were compared with patients not receiving sirolimus. RESULTS: Postoperative infections occurred in 19.2% of the sirolimus group (n=26) and 5.4% of the controls (n=37; p=.11; odds ratio [OR], 4.2; 95% confidence interval [CI], 0.7-23.4). The incidence of wound dehiscence was greater in the sirolimus group (7.7% vs. 0%; p=.17; OR, 7.7; 95% CI, 0.4-166.3). CONCLUSION: No significantly increased risk of wound complications was found in organ transplant recipients receiving sirolimus while undergoing dermatologic surgery. However, this study was retrospective and had a small sample size. A larger study is necessary for corroboration.

AB - BACKGROUND: Sirolimus, a TOR (target of rapamycin)-binding immunosuppressant, has been associated with wound healing complications; however, its effects have not been documented in dermatologic surgery. OBJECTIVE: The objective was to determine the effect of sirolimus on wound healing in dermatologic surgery. METHODS AND MATERIALS: Databases at Mayo Clinic were queried for organ transplant recipients undergoing dermatologic surgery. Medical records were reviewed retrospectively, and telephone interviews were conducted. Patients receiving sirolimus were compared with patients not receiving sirolimus. RESULTS: Postoperative infections occurred in 19.2% of the sirolimus group (n=26) and 5.4% of the controls (n=37; p=.11; odds ratio [OR], 4.2; 95% confidence interval [CI], 0.7-23.4). The incidence of wound dehiscence was greater in the sirolimus group (7.7% vs. 0%; p=.17; OR, 7.7; 95% CI, 0.4-166.3). CONCLUSION: No significantly increased risk of wound complications was found in organ transplant recipients receiving sirolimus while undergoing dermatologic surgery. However, this study was retrospective and had a small sample size. A larger study is necessary for corroboration.

UR - http://www.scopus.com/inward/record.url?scp=38349138918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349138918&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4725.2007.34040.x

DO - 10.1111/j.1524-4725.2007.34040.x

M3 - Article

C2 - 18093198

AN - SCOPUS:38349138918

VL - 34

SP - 216

EP - 223

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 2

ER -